Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0000950170-25-060573
Filing Date
2025-04-30
Accepted
2025-04-30 07:30:16
Documents
24

Document Format Files

Seq Description Document Type Size
1 DEFR14A eq-20250430.htm   iXBRL DEFR14A 1843623
2 GRAPHIC img2531299_0.jpg GRAPHIC 244396
3 GRAPHIC img2531299_1.jpg GRAPHIC 14129
4 GRAPHIC img2531299_2.jpg GRAPHIC 100054
5 GRAPHIC img2531299_3.jpg GRAPHIC 126840
6 GRAPHIC img2531299_4.jpg GRAPHIC 431654
7 GRAPHIC img2531299_5.jpg GRAPHIC 404342
8 GRAPHIC img2531299_6.jpg GRAPHIC 14129
9 GRAPHIC img2531299_7.jpg GRAPHIC 605999
10 GRAPHIC img2531299_8.jpg GRAPHIC 442036
  Complete submission text file 0000950170-25-060573.txt   8380614

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eq-20250430.xsd EX-101.SCH 26919
27 EXTRACTED XBRL INSTANCE DOCUMENT eq-20250430_htm.xml XML 184627
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037 (858) 412-5302
Equillium, Inc. (Filer) CIK: 0001746466 (see all company filings)

EIN.: 821554746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 001-38692 | Film No.: 25890995
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)